Compare MEI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | BCYC |
|---|---|---|
| Founded | 1946 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.7M | 310.7M |
| IPO Year | 1994 | 2019 |
| Metric | MEI | BCYC |
|---|---|---|
| Price | $11.27 | $4.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $9.00 | ★ $13.90 |
| AVG Volume (30 Days) | ★ 1.2M | 356.1K |
| Earning Date | 03-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 49.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $908,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $4.88 | $4.24 |
| 52 Week High | $15.55 | $9.36 |
| Indicator | MEI | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 43.70 |
| Support Level | $6.67 | $4.52 |
| Resistance Level | $15.55 | $5.31 |
| Average True Range (ATR) | 1.28 | 0.20 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 34.77 | 31.25 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.